Prospective Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 26, 2022; 10(33): 12208-12220
Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12208
Predictors of bowel damage in the long-term progression of Crohn’s disease
Agnes Fernández-Clotet, Julian Panés, Elena Ricart, Jesús Castro-Poceiro, Maria Carme Masamunt, Sonia Rodríguez, Berta Caballol, Ingrid Ordás, Jordi Rimola
Agnes Fernández-Clotet, Julian Panés, Elena Ricart, Jesús Castro-Poceiro, Maria Carme Masamunt, Berta Caballol, Ingrid Ordás, Department of Gastroenterology, Hospital Clinic, Barcelona 08036, Spain
Agnes Fernández-Clotet, Julian Panés, Elena Ricart, Jesús Castro-Poceiro, Maria Carme Masamunt, Berta Caballol, Ingrid Ordás, Universitat de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona 08036, Spain
Agnes Fernández-Clotet, Julian Panés, Elena Ricart, Jesús Castro-Poceiro, Maria Carme Masamunt, Berta Caballol, Ingrid Ordás, Jordi Rimola, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, CIBEREHD, Madrid 28029, Spain
Sonia Rodríguez, Jordi Rimola, Department of Radiology, Hospital Clinic, Barcelona 08036, Spain
Author contributions: Fernández-Clotet A contributed to study design, study conduction, patient recruitment, data collection, data analysis, data interpretation, and drafting the article; Panés J, Ordás I, and Rimola J contributed to study design, patient recruitment, data collection, data interpretation, and drafting the article; Ricart E, Castro-Poceiro J, Masamunt MC, and Caballol B contributed to patient recruitment and data collection; Rodríguez S contributed to data collection; all authors critically reviewed the article and approved the final manuscript.
Supported by the Helmsley Charitable Trust Grant, No. 2015PG-IBD005.
Institutional review board statement: This study was evaluated and approved by the Local Ethics Committee (Approval No. HCB/2018/0160).
Clinical trial registration statement: This study is registered at the clinical hospital center “Hospital Clinic de Barcelona”. The registration identification number is HCB/2018/0160.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: Dr. Rimola reports grants from Abbvie, personal fees from Alimentiv, personal fees from Janssen, personal fees from Takeda, non-financial support from Gilead and from Agumab during the conduct of the study.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jordi Rimola, MD, PhD, Consultant Physician-Scientist, Department of Radiology, Hospital Clinic, 170 Villarroel, Barcelona 08036, Spain. jrimola@clinic.cat
Received: September 14, 2022
Peer-review started: September 14, 2022
First decision: September 26, 2022
Revised: October 6, 2022
Accepted: October 31, 2022
Article in press: October 31, 2022
Published online: November 26, 2022
ARTICLE HIGHLIGHTS
Research background

Crohn’s disease (CD) progresses to bowel damage (BD) over time. An image-based index, the Lémann index (LI), has been developed and validated to measure cumulative BD. The LI consists of a scoring system based on a comprehensive assessment of structural BD, which includes the identification of stricturing and penetrating lesions based on cross-sectional imaging and endoscopy, and previous surgery.

Research motivation

Risk factors for BD progression are not well identified. Studies that evaluate damage severity have a short period of observation, whereas damage accumulates over long periods of time.

Research objectives

To characterize the long-term progression of BD in patients with CD based on changes in the LI, to identify which components of the index are the main determinants of progression, and to identify risk factors for long-term progression.

Research methods

We performed a longitudinal cohort study in the tertiary referral center Hospital Clinic of Barcelona from April 2018 to December 2019. We took advantage of our patient cohorts that had participated in past studies on the accuracy of magnetic resonance imaging for characterizing CD inflammatory activity using endoscopy as the gold standard. We invited patients that had undergone these examinations within the past 5 years to 12 years to be re-evaluated in the context of the current study. BD and its progression over time were assessed for each patient using the LI and calculated at baseline and at the second assessment.

Research results

Seventy-two patients were included. LI increased in 38 patients (52.8%), remained unchanged in 9 patients (12.5%), and decreased in 25 patients (34.7%). The small bowel score and surgery subscale significantly increased (P = 0.002 and P = 0.001, respectively), whereas the fistulizing subscale significantly decreased (P = 0.001). Baseline parameters associated with BD progression were ileal location (P = 0.026), CD phenotype (stricturing, fistulizing, or both with P = 0.007, P = 0.006, and P = 0.035, respectively), disease duration > 10 years (P = 0.019), and baseline LI stricturing score (P = 0.049).

Research conclusions

BD, as assessed by the LI, progressed in half of the patients with CD over a period of 5-12 years. The main determinants of BD progression are ileal location, stricturing/fistulizing phenotype, and disease duration.

Research perspectives

The timepoint to evaluate BD progression is still not yet established. Some treatment can prevent BD progression, but we still do not have robust data to confirm these findings.